Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Three-year efficacy of switching to dolutegravir plus lamivudine: A real-world study.
Palmier E, De Miguel R, Montejano R, Busca C, Micán R, Ramos L, Cadiñanos J, Serrano L, Bernardino JI, Pérez-Valero I, Valencia E, Arribas JR, Montes ML, González-García J, Martín-Carbonero L. Palmier E, et al. HIV Med. 2023 Sep;24(9):1013-1019. doi: 10.1111/hiv.13500. Epub 2023 May 16. HIV Med. 2023. PMID: 37194419
HCV spontaneous clearers showed low senescence profile in people living with HIV under long ART.
Lara-Aguilar V, Crespo-Bermejo C, Llamas-Adán M, Grande-García S, Cortijo-Alfonso ME, Martín-Carbonero L, Domínguez L, Ryan P, de Los Santos I, Bartolomé-Sanchez S, Valle-Millares D, Jiménez-Sousa MÁ, Briz V, Fernández-Rodríguez A; Multidisciplinary HIV/Hepatitis Viral Coinfection Group (COVIHEP). Lara-Aguilar V, et al. J Med Virol. 2023 Jul;95(7):e28955. doi: 10.1002/jmv.28955. J Med Virol. 2023. PMID: 37465865
Corrigendum to "Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)".
De Miguel R, Rial-Crestelo D, Dominguez-Dominguez L, Montejano R, Esteban-Cantos A, Aranguren-Rivas P, Stella-Ascariz N, Bisbal O, Bermejo-Plaza L, Garcia-Alvarez M, Alejos B, Hernando A, Santacreu-Guerrero M, Cadiñanos J, Mayoral M, Castro JM, Moreno V, Martin-Carbonero L, Delgado R, Rubio R, Pulido F, Arribas JR; ART-PRO, PI16/00837-PI16/00678 study group. De Miguel R, et al. EBioMedicine. 2023 Mar;89:104486. doi: 10.1016/j.ebiom.2023.104486. Epub 2023 Feb 18. EBioMedicine. 2023. PMID: 36806001 Free PMC article. No abstract available.
Dynamics of cellular senescence markers after HCV elimination spontaneously or by DAAs in people living with HIV.
Lara-Aguilar V, Valle-Millares D, Crespo-Bermejo C, Grande-García S, Llamas-Adán M, Cortijo-Alfonso ME, Martín-Carbonero L, Domínguez L, Ryan P, de Los Santos I, Bartolomé-Sánchez S, Vidal-Alcántara EJ, Jiménez-Sousa MA, Fernández-Rodríguez A, Briz V; Multidisciplinary HIV/Hepatitis Viral Coinfection Group (COVIHEP). Lara-Aguilar V, et al. Biomed Pharmacother. 2023 Jun;162:114664. doi: 10.1016/j.biopha.2023.114664. Epub 2023 Apr 7. Biomed Pharmacother. 2023. PMID: 37031491 Free article.
193 results